AFP and seminoma: The novel marker M371 outperforms all classical markers with expression rates of 82.7% and 93.6% in seminoma and nonseminoma, respectively, and these rates are also significantly higher than the combined rate of AFP and/ or bHCG in nonseminoma (68.7%).